The intravenous use of high molecular ferric carbohydrate compound in the treatment of hypochromic anemia.

By JOHN E. LUCAS, M.D. AND ALBERT B. HAGEDORN, M.D. T HE ORAL USE of iroms ins tise treatmemst of irons deficienicv ansemia has heens well established! amid documensted. However, the paremsteral use of this metal ins the treatment of hypochromic ansemia dine to irons demmcienscy has, ins the past-, been limited by the inscidemsce of toxic reactionss si-hems ansy hut suboptimal doses of the preparatiomus of irons have beemi unsed.’4 Ins 1947 Nissim5 reported oms thie initravenous use of saccharat-ed irons oxide ins the treatmenst of hypochromic ansemia. Since then a miumber of reports oms its use ins the treatmenst of this type of anemia have appeared! ins the literatunre.6’9 Saccharated irons oxidle is a niegatively charged cOllOid!al solumtioni of irons oxyhydrate stabilized by adsorptions of alkali amid sumgar.’8 Althoungh toxic react-ionss have occurred with the instravemsouns use of saccharated irons oxide,6 20 their inscidence amid severity have nsot preclumdbedb its admimsistratioms as a thserapetmt-ic ageist ins selected cases. Ins this paper, data ons the use of highs molecunlar ferric carbohydirate compounmsd ins the treatmemit of 20 patients are presenstedi. Our primary aim was to evaluate the usefulmsess of this preparations of irons wheni givens imstravemsously to patiemsts svith hypochromic amsemia.